Proteomic based approaches are continuing to play a major role in studying the natural history and treatment of various diseases. For example, proteomics can facilitate discovery of new molecular targets for therapy, biomarkers for early detection, and new endpoints for therapeutic efficacy and toxicity. Moreover, real-time information about the states of intracellular signaling pathways in the normal and diseased state before, during and after therapy can potentially be obtained to guide individualized treatment.
Identification of specific and sensitive markers of a disease is an important public health concern and proteomic technologies will play a key role in discovering protein targets. The new frontiers in proteomics will have to be concerned with identifying and validating all useful “druggable” targets. Such information is of paramount importance in designing drugs for every single or group of protein targets implicated in a disease. For example, it is becoming increasingly clear that many drug targets (e.g. kinases, proteases, etc.) share discrete signatures that are more reflective of their 3D architecture, highlighting that a common set of enzymes may be targeted by similar classes of small-molecule drugs. This presentation will highlight new technologies and challenges in post-proteomics era.
Copyright. All Rights Reserved.